Friday, 27 November 2020

FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma



source https://www.pharmatutor.org/pharma-news/2020/fda-approves-y-mabs-danyelza-naxitamab-gqgk-for-the-treatment-of-neuroblastoma
at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Pharma openings

  Opportunity for M.Pharm, Msc or PhD as Scientist at PGIMER M.Pharmacy or M.Sc 6 Year of Research Experience or PhD with 3 year of Experien...